In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Bottom line: Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 ...
Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are ...
Notably, Insilico’s self-developed Chemistry42 played a crucial role in this research by generating the pyrrolopyrazine carboxamide core as a starting point for further molecular design. Moreover, ...
Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma Recurrent nonkinase domain FGFR VUS variants were collected from the Catalog of Somatic Mutations in Cancer and their ...
Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane tyrosine kinase that regulates signaling pathways controlling cell survival and proliferation. Dysregulation of FGFR2, through ...
Bent bone dysplasia (BBD) is a perinatal-lethal skeletal disorder caused by pathogenic FGFR2 mutations that disrupt bone formation, leading to bent long bones, osteopenia, and craniosynostosis. Bent ...
SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the ...
Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results